Citius Oncology Inc (CTOR)

Dec 10, 2025

Citius Oncology Raises $18M Through Direct Offering - TipRanks

Dec 10, 2025

Dec 10, 2025

Citius Oncology closes $18 million in offerings to support LYMPHIR launch - Investing.com Canada

Dec 10, 2025

Dec 10, 2025

Citius Oncology Announces Closing of $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules - PR Newswire

Dec 10, 2025

Dec 09, 2025

Citius Oncology raises $18 million to support cancer therapy launch By Investing.com - Investing.com Canada

Dec 09, 2025

Dec 09, 2025

Citius Oncology shares sink after announcing $18M fundraising deal - MSN

Dec 09, 2025

Dec 09, 2025

Citius Oncology stock tumbles after $18M capital raise By Investing.com - Investing.com UK

Dec 09, 2025

Dec 09, 2025

Citius Oncology stock tumbles after $18M capital raise - Investing.com

Dec 09, 2025

Dec 09, 2025

Citius Oncology announces $18 million concurrent registered direct offering and private placement priced at-the-market under Nasdaq rules - marketscreener.com

Dec 09, 2025

Dec 09, 2025

Citius Oncology Announces $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules - Benzinga

Dec 09, 2025

Dec 06, 2025

What drives Citius Oncology Inc stock priceStock Price Divergence & Calculate Profit Targets With AI Accuracy - earlytimes.in

Dec 06, 2025

Dec 06, 2025

Is Citius Oncology Inc a good long term investmentLow Beta Stocks & Free Rapid Profit Acceleration - earlytimes.in

Dec 06, 2025

Dec 05, 2025

Citius Oncology Launches Lymphir In US For Skin Cancer - MSN

Dec 05, 2025

Dec 05, 2025

Citius Oncology expands lymphir distribution to Turkey, Middle East By Investing.com - Investing.com Nigeria

Dec 05, 2025

Dec 05, 2025

Is Citius Oncology Inc. stock a top pick in earnings season2025 Dividend Review & Weekly Top Gainers Alerts - Newser

Dec 05, 2025

Dec 04, 2025

Citius Oncology Expands LYMPHIR™ Distribution to Turkey and Middle East Countries Through Exclusive Agreement with Er-Kim - The Malaysian Reserve

Dec 04, 2025

Dec 04, 2025

Citius Oncology expands lymphir distribution to Turkey, Middle East - Investing.com

Dec 04, 2025

Dec 04, 2025

Citius Oncology expands Lymphir distribution to Turkey and Middle East countries - marketscreener.com

Dec 04, 2025

Dec 04, 2025

Citius Oncology Expands Lymphir Distribution To Turkey And Middle East Countries - TradingView

Dec 04, 2025

Dec 04, 2025

What Wall Street predicts for Citius Oncology Inc. stock priceStop Loss & Growth Focused Stock Pick Reports - Newser

Dec 04, 2025

Dec 03, 2025

Citius Oncology launches Lymphir treatment for rare lymphoma - NJBIZ

Dec 03, 2025

Dec 02, 2025

Citius Oncology enters distribution services agreement with Cardinal Health - MSN

Dec 02, 2025

Dec 02, 2025

Does Citius Oncology Inc (CTOR) offer a good opportunity for investors? - Setenews

Dec 02, 2025

Dec 02, 2025

Citius Oncology Announces U.S. Commercial Launch of LYMPHIR, a Novel Cancer Immunotherapy for Cutaneous T-Cell Lymphoma (CTCL) - marketscreener.com

Dec 02, 2025

Dec 02, 2025

Citius Oncology (CTOR) Stock Analysis Report | Financials & Insights - Benzinga

Dec 02, 2025

Dec 02, 2025

Citius launches Lymphir in USA for relapsed or refractory CTCL - The Pharma Letter

Dec 02, 2025

Dec 02, 2025

Citius Oncology Launches LYMPHIR, The First CTCL Systemic Therapy In Over 7 Years - Nasdaq

Dec 02, 2025

Dec 02, 2025

Citius Pharmaceuticals Launches LYMPHIR for T-Cell Lymphoma - MSN

Dec 02, 2025

Dec 02, 2025

Will Citius Oncology Inc. stock continue upward momentumJuly 2025 Market Mood & Target Return Focused Picks - Newser

Dec 02, 2025

Dec 02, 2025

Citius Oncology Announces U.S. Commercial Launch of LYMPHIRtm, a Novel Cancer Immunotherapy for Cutaneous T-Cell Lymphoma (CTCL) - Lelezard

Dec 02, 2025

Dec 02, 2025

CTORCitius Oncology, Inc. Latest Stock News & Market Updates - Stock Titan

Dec 02, 2025

Dec 02, 2025

How Citius Oncology Inc. stock performs in weak economyWeekly Earnings Recap & Low Risk High Reward Ideas - Newser

Dec 02, 2025

Dec 01, 2025

Citius Oncology Launches LYMPHIR for Cutaneous T-Cell Lymphoma - TipRanks

Dec 01, 2025

Dec 01, 2025

Citius Oncology, Inc. Announces U.S. Launch of LYMPHIR for CTCL - TradingView

Dec 01, 2025

Dec 01, 2025

Citius Oncology : Amendment to Statement of Changes in Beneficial Ownership (Form 4/A) - marketscreener.com

Dec 01, 2025

Dec 01, 2025

Citius Oncology announces U.S. commercial launch of Lymphir for cutaneous T-cell lymphoma - marketscreener.com

Dec 01, 2025

Dec 01, 2025

Citius Oncology stock soars after commercial launch of LYMPHIR therapy By Investing.com - Investing.com South Africa

Dec 01, 2025

Dec 01, 2025

Citius Oncology stock soars after commercial launch of LYMPHIR therapy - Investing.com India

Dec 01, 2025

Dec 01, 2025

Citius Oncology rises after U.S. launch of Lymphir as a cancer treatment - Seeking Alpha

Dec 01, 2025

Dec 01, 2025

Citius Oncology Launches Cancer Drug Lymphir in the US - marketscreener.com

Dec 01, 2025

Dec 01, 2025

Citius Oncology launches lymphir for cutaneous T-cell lymphoma By Investing.com - Investing.com South Africa

Dec 01, 2025

Dec 01, 2025

Citius Oncology launches lymphir for cutaneous T-cell lymphoma - Investing.com

Dec 01, 2025

Dec 01, 2025

Citius Oncology Launches Lymphir In US For Skin Cancer — Retail Traders Eye Major Upside - Stocktwits

Dec 01, 2025

Dec 01, 2025

Citius Oncology Announces U.S. Commercial Launch of LYMPHIR™, a Novel Cancer Immunotherapy for Cutaneous T-Cell Lymphoma (CTCL) – Company Announcement - Financial Times

Dec 01, 2025

Nov 28, 2025

Citius Oncology Establishes International Access to LYMPHIR™ via Named Patient Programs in Southern Europe - Aktiellt

Nov 28, 2025

Nov 28, 2025

Citius Oncology, Inc. (CTOR) Jumps 6% in Pre-market: Following ASH Annual Meeting Announcement - Stocks Telegraph

Nov 28, 2025

Nov 26, 2025

Citius Oncology Deploys AI Platform to Amplify the Performance of its Commercial Team Ahead of LYMPHIR Launch - Aktiellt

Nov 26, 2025